Legend Biotech Boasts $555M Q4 CARVYKTI Sales, Profitability and 10,000 Patients Treated
Legend Biotech posted CARVYKTI net trade sales of $555 million in Q4 and $1.9 billion for 2025, achieved franchise profitability and treated over 10,000 patients. The company ended the period with $949 million in cash and equivalents, expanded its Raritan manufacturing site and initiated first-in-human dosing for allogeneic CAR-T candidates.
1. Strong CARVYKTI Sales and Profitability
In Q4 2025, CARVYKTI net trade sales reached $555 million, contributing to a full-year total of $1.9 billion. The therapy achieved franchise-level profitability for the first time and has now been administered to over 10,000 patients worldwide.
2. Manufacturing Expansion at Raritan
Legend Biotech completed the expanded portion of its Raritan, New Jersey facility, making it the largest cell therapy manufacturing site in the U.S. The upgraded site supports annual production for up to 10,000 patients, bolstering capacity for growing CARVYKTI demand.
3. Pipeline and Clinical Advancements
The company advanced its early-stage cell therapy portfolio by dosing the first patient with in vivo candidates and presenting first-in-human data for LUCAR-G39D, an allogeneic CAR-T therapy in B-cell non-Hodgkin lymphoma. A new 31,000-square-foot R&D facility opened in Philadelphia to support these programs.
4. Strong Cash Position
As of December 31, 2025, Legend Biotech held $949 million in cash, cash equivalents and time deposits. This robust balance sheet provides financial runway beyond 2026, supporting ongoing operations and pipeline development.